CoC Measures for Quality of Cancer Care
Cancer registry data elements are nationally standardized and considered open source. Each of these measures was developed by the CoC with the expectation that cancer registries would be used to collect the necessary data to assess and monitor concordance with the measures. Extensive assessment and validation of the measures was performed using cancer registry data reported to the National Cancer Database (NCDB).
All measures are designed to assess performance at the hospital or systems-level, and are not intended for application to individual physician performance.
|
Primary Site
|
Measure Type
|
2016 Standard and Expected EPR
|
Measure Description
|
Initial CP3R Release
|
|
Bladder
|
|
|
|
|
|
BL2RLN
|
S
|
Not Applicable
|
At least 2 lymph nodes are removed in patients under 80 undergoing partial or radical cystectomy
|
Spring 2016
|
|
BLCSTRI
|
S
|
Not Applicable
|
Radical or partial cystectomy; or Tri-modality therapy (Local tumor destruction/excision with chemotherapy and radiation) for clinical T234N0M0 patients, first treatment within 90 days of diagnosis
|
Spring 2017
|
|
BLCT
|
S
|
Not Applicable
|
Neo-adjuvant or adjuvant chemotherapy offered or administered for patients with muscle invasive cancer undergoing radical cystectomy
|
Spring 2017
|
|
Breast
|
|
|
|
|
|
BCSRT
|
A
|
Standard 4.4
90%
|
(NQF #219) Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer.
|
Fall 2008
|
|
MAC
|
A
|
Not Applicable
|
(NQF #0559) Combination chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or stage IB - III hormone receptor negative breast cancer.
|
Fall 2008
|
|
HT
|
A
|
Standard 4.4
90%
|
(NQF #0220) Tamoxifen or third generation aromatase inhibitor is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0, or stage IB - III hormone receptor positive breast cancer..
|
Fall 2008
|
|
MASTRT
|
A
|
Standard 4.4
90%
|
Radiation therapy is recommended or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with ≥ 4 positive regional lymph nodes.
|
Spring 2014
|
|
nBx
|
QI
|
Standard 4.5
80%
|
Image or palpation-guided needle biopsy to the primary site is performed to establish diagnosis of breast cancer.
|
Spring 2014
|
|
BCS
|
S
|
Not Applicable
|
Breast conservation surgery rate for women with AJCC clinical stage 0, I, or II breast cancer.
|
Spring 2014
|
|
Cervix
|
|
|
|
|
|
CBRRT
|
S
|
Not Applicable
|
Use of brachytherapy in patients treated with primary radiation with curative intent in any stage of cervical cancer
|
Spring 2015
|
|
CERRT
|
S
|
Not Applicable
|
Radiation therapy completed within 60 days of initiation of radiation among women diagnosed with any stage of cervical cancer
|
Spring 2015
|
|
CERCT
|
S
|
Not Applicable
|
Chemotherapy administered to cervical cancer patients who received radiation for stages IB2-IV cancer (Group 1) or with positive pelvic nodes, positive surgical margin, and/or positive parametrium (Group 2)
|
Fall 2015
|
|
Colon
|
|
|
|
|
|
ACT
|
A
|
Not Applicable
|
(NQF #0223) Adjuvant chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer.
|
Fall 2008
|
|
12RLN
|
QI
|
Standard 4.5
85%
|
(NQF #0225) At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer.
|
Fall 2008
|
|
Endometrium
|
|
|
|
|
|
ENDCTRT
|
S
|
Not Applicable
|
Chemotherapy and/or radiation administered to patients with Stage IIIC or IV Endometrial cancer
|
Fall 2015
|
|
ENDLRC
|
S
|
Not Applicable
|
Endoscopic, laparoscopic, or robotic surgery performed for all Endometrial cancer (excluding sarcoma and lymphoma), for all stages except stage IV
|
Fall 2015
|
|
Gastric
|
|
|
|
|
|
G15RLN
|
QI
|
Standard 4.5
80%
|
At least 15 regional lymph nodes are removed and pathologically examined for resected gastric cancer.
|
Fall 2014
|
|
Kidney
|
|
|
|
|
|
PD1RLN
|
S
|
|
Pediatric Measure: At least 1 regional lymph node is removed and pathologically examined for primarily resected unilateral nephroblastoma
|
Spring 2017
|
|
Non-Small Cell Lung
|
|
|
|
|
|
10RLN
|
S
|
Not Applicable
|
At least 10 regional lymph nodes are removed and pathologically examined for AJCC stage IA, IB, IIA, and IIB resected NSCLC
|
Fall 2014
|
|
LCT
|
QI
|
Standard 4.5
85%
|
Systemic chemotherapy is administered within 4 months to day preoperatively or day of surgery to 6 months postoperatively, or it is recommended for surgically resected cases with pathologic, lymph node-positive (pN1) and (pN2) NSCLC.
|
Fall 2014
|
|
LNoSurg
|
QI
|
Standard 4.5
85%
|
Surgery is not the first course of treatment for cN2, M0 lung cases
|
Spring 2015
|
|
Ovary
|
|
|
|
|
|
OVSAL
|
S
|
Not Applicable
|
Salpingo-oophorectomy with omentectomy, debulking; cytoreductive surgery, or pelvic exenteration in Stages I-IIIC Ovarian cancer
|
Fall 2015
|
|
Rectum
|
|
|
|
|
|
RECRTCT
|
QI
|
Standard 4.5
85%
|
Preoperative chemo and radiation are administered for clinical AJCC T3N0, T4N0, or Stage III; or Postoperative chemo and radiation are administered within 180 days of diagnosis for clinical AJCC T1-2N0 with pathologic AJCC T3N0, T4N0, or Stage III; or treatment is recommended; for patients under the age of 80 receiving resection for rectal cancer.
|
Spring 2015
|
A - Accountability; QI - Quality Improvement; S- Surveillance
Bladder Measure Specifications
Breast Measure Specifications
Cervix Measure Specifications
Colon Measure Specifications
Endometrium Measure Specifications
Gastric Measure Specifications
Kidney Measure Specifications
Non-Small Cell Lung Measure Specifications
Ovary Measure Specifications
Rectum Measure Specifications
Measure Specification Modifications
Measure Changes and Release Notes
For questions related to the release of these quality measures, please contact the NCDB at ncdb@facs.org.